Financial Performance - UFP Technologies reported 2024 net income of 59.0million,a31.344.9 million in 2023, with adjusted net income growing 32.5% to 67.6million[2].−Netsalesfor2024reached504.4 million, up 26.1% from 400.1millionin2023,whilefourth−quartersalesincreased41.9144.1 million compared to 101.5millioninQ42023[3][5].−Thecompany′sgrossmarginimprovedto29.226.0 million, while full-year adjusted operating income increased 40.4% to 92.3million[9].−UFPTechnologiesexperiencedorganicgrowthof6.7132.7 million, with full-year MedTech sales up 30.2% to 450.8million[5].CashFlowandAssets−Cashandcashequivalentsincreasedto13.45 million in 2024 from 5.26millionin2023,whiletotalassetsroseto628.99 million from 404.14million[10].−Totalliabilitiesincreasedto286.24 million in 2024 from 118.05millionin2023,withlong−termdebtrisingto176.88 million from 28.00 million[10]. Operating Expenses - Adjusted SG&A (Non-GAAP) for Q4 2024 was 16,094, compared to 12,020inQ42023,representinganincreaseof33.362,218, up from 50,889in2023,anincreaseof22.319,163, up from 12,640inQ42023,reflectingagrowthof51.92.46 in Q4 2024 from 1.64inQ42023,ariseof50.027,133, compared to 15,607inQ42023,markingasignificantincreaseof73.8107,321, up from 77,167inthepreviousyear,anincreaseof39.116,375, compared to 11,607inQ42023,representinganincreaseof41.02,520, compared to 0in2023[19].−AmortizationofintangibleassetsforthetwelvemonthsendedDecember31,2024,was6,727, up from $4,403 in 2023, an increase of 52.8%[19]. Shareholder Information - The weighted average diluted common shares outstanding increased slightly to 7,794 in Q4 2024 from 7,712 in Q4 2023[19].